<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR5">
 <label>5.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Shirasaka</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Shimamato</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Ohshimo</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Yamaguchi</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Kato</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Yonekura</surname>
    <given-names>KFM</given-names>
   </name>
  </person-group>
  <article-title>Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators</article-title>
  <source>Anti-Cancer Drugs</source>
  <year>1996</year>
  <volume>7</volume>
  <fpage>548</fpage>
  <lpage>557</lpage>
  <pub-id pub-id-type="doi">10.1097/00001813-199607000-00010</pub-id>
  <pub-id pub-id-type="pmid">8862723</pub-id>
 </element-citation>
</ref>
